Second-line combination therapies in nonsmall cell lung cancer without known driver mutations.

Eur Respir Rev · 2015 · PMC9487623 · PMID 26621972

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

No significant difference was seen for the primary end-point (HR 0.97, p=0.7583), although a nonsignificant trend for benefit in PFS and response rate was apparent.

also in 5,406 other papers

showed a trendno p-value reported

The results showed a trend for improved survival and a rate response benefit with an acceptable toxicity profile in patients with EGFR-expressing tumours .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.